Resume Sample for Director (Immuno-Pharmacology)

picture of Director (Immuno-Pharmacology) resume sample sheet
The following is an example of Director (Immuno-Pharmacology) resume sample. Reviewing the candidate's full work experience, outlining key-qualifications, duties and responsibilities for the Pharmaceuticals job title/field.

Resume Writing Example for Director (Immuno-Pharmacology) | CV Format

Director (Immuno-Pharmacology) – Pharmacyclics

Pinole, CA

Oncologist/Geneticist with 20+ years of post-PhD experience in both academic and industrial 
settings, with an emphasis on project and functional leadership, animal models of human cancer, immuno- 
oncology and genetic diseases, testing of novel therapeutics for drug development with antibodies (naked, bi- 
specific and ADC)/ antisense oligos (ASOs)/ small molecule compounds, identification of disease related bio- 
markers, and characterization of novel genes and non-coding RNAs. 
• Demonstrated ability to lead projects and cross-functional teams. Serve as research representative in 
multiple clinical teams to monitor the on-going trials for Ibrutinib and Abexinostat at Pharmacyclics. Led 
cross-functional teams at Pharmacyclics/Agensys/Ionis/Xoma to support the drug development programs. 
Served as a project leader in the partnered EphB3 program (Novartis-Chiron/XOMA collaboration) and led 
the project from antibody generation through milestones. Served as the pharmacology representative in 
multiple project teams (in collaboration with Chiron/Novartis, Takeda, Schering Plough/Merck, 
AstraZeneca and Ambrx) and the single point of contact with multiple CROs. 
• Strong leadership and managerial skills. Manage up to 10 research associates/PhD scientists in a daily 
base manner focusing on the areas of in vitro assay, in vivo efficacy, immuno-phenotyping, PD/biomarker 
and preliminary PK/Tox studies; and take responsibilities of career development for the direct reports. 
• Experience with translational biology. Hands on experience with executing in vivo bio-imaging studies 
using Optical (Bioluminescence, Fluorescence) and micro PET/CT imaging modalities to develop the 
companion diagnostic assays for AGS-22M6E; and identified disease related pharmacodynamic (PD) 
biomarkers for Ibrutinib, Abexinostat, Lucatumumab, ISIS-STAT3Rx and ISIS-Malat1 using FACS, qPCR, 
MSD and Luminex platforms. 
• Extensive experience with in vitro assays and molecular biology for analyses of gene functions. 
Identified and cloned 2 novel cancer related genes (FETUB and HGR); characterized multiple 
cancer/genetic disease genes with detail molecular structures. 
• Exceptional knowledge and experience of all types of in vivo cancer models and their use in 
discovering and developing anti-cancer drugs. Hands on experience with developing and validating more 
than 235 subcutaneous xenografts (in both of solid and liquid tumor types), 21 orthotopic xenografts, 191 
PDXs (patient derived xenografts), 20 syngeneic, 15 dissemination/metastasis, 2 cachexia and 10 
metabolic/inflammatory models; and bred/characterized more than 25 knock in/out transgenic mouse 
• Good track record of scientific inputs. Research data was published in more than 41+ publications and 
9+ patent applications.

Work Experience

Director (Immuno-Pharmacology)


Sunnyvale, CA

January 2015 to Present

Lead a group of 5-10 researchers in various aspects of immuno-oncology research and cancer immunotherapies, from selecting and characterizing lead compounds, to identify their mechanism of action in cancer including 
solid tumors and hematology-oncology, to support initial preclinical research for clinical candidates, to test 
novel combinations with other therapeutics. Focus on developing and running biochemical, immunologic and in vivo assays to support the development of small molecules including those that function as immune modulators for the treatment of cancer. Manage both internal (including in-house and two other satellite sites) and external 
resources (CROs and academic collaborators) in pharmacology to generate pre-clinical packages including 
efficacy/PK/PD relationship and immune-phenotyping to support IND filing and the on-going clinical trials. 
Breed and utilize the state-of-the-art genetically engineered mice (KPC and Eμ-TCL1) for target discovery and drug development. Serve as the research representative in multiple clinical teams to discover and develop 
PD/Biomarkers to monitor clinical trials. The up-to-date achievements include: utilized ~ 7 million dollar 
budget per year in outsourcing pharmacology and immuno-oncology studies; obtained in vivo proof of concept for Ibrutinib and BTKi in multiple disease indications including different solid tumors, hematology-oncology 

and cGvHD; monitored and executed more than 160 in vivo studies in house; completed multiple clinical study 
reports (CSRs), consensus information forms (CISs) and the investigation brochure (focusing on the 
PD/Biomarker section) for the clinical trials of Abexinostat (a pan-HDAC inhibitor). The data package of 
Abexinostat ended up with a out-licensing deal with Xynomic. As for today, 10 publications and 4 patents were 

Assistant Director/Project Leader

Astellas (Agensys)

Santa Monica, CA

January 2012 to January 2015

Provide pharmacology support for regulatory filings including INDs. Lead a team of lab-based research 
scientists within the In Vivo Pharmacology Department. Develop the in vitro and in vivo pharmacology research 
strategy in a team environment. Lead a cross-functional project team and manage programs, deliverable, 
timelines and budgets. Oversee the entire pharmacology function for the Astellas/Ambrx collaboration. 
Establish and enable the in vivo imaging capabilities. Duties include: developing and implementing models of human cancer in rodents; designing and implementing efficacy studies; conducting preliminary PK/PD and Tox 
studies; serving as the pharmacology representative in multiple project teams including target discovery and development programs; executing the internal efforts of preclinical in vivo Bio-Imaging studies using Optical 
(Bioluminescence, Fluorescence) and micro PET/CT imaging modalities to evaluate therapeutic antibodies and antibody drug conjugates; writing IACUC protocols for in vivo Imaging studies. The up-to-date achievements 
include: completed the imaging data sets (in both of PET/CT and Optical modalities) to support the strategy of patient selection for Agensys’ ADC which is currently in clinic trails; established a unique and sophisticated 
patient derived xenograft (PDX) bank and LIM-based database with detail characterizations of pharmacology, 
molecular biology and histology; established and characterized a panel of prostate tumor models to test the 
Astellas’ approved compound (Enzalutamide); executed the pilot, efficacy, PK/Tox and MOA studies in house by utilizing more than 23000 SCID mice annually; filed one IND and moved the product into clinical 
development (AGS67E; IND 118989). 3 publications and 1 patent were published throughout this period.

Principal Scientist

Ionis Pharmaceuticals

Carlsbad, CA

October 2010 to January 2012

Performed in vivo pharmacology focusing on the area of oncology; duties included: developing and implementing models of human cancer in rodents; designing and implementing efficacy studies in collaboration with different functional leads; developing strategies for evaluating therapeutic mechanisms of action; 
identifying and validating biomarkers; maintaining, expanding, and characterizing the collection of cancer cell 
lines and tumor xenografts; breeding colonies of various mouse strains; supporting ASO (antisense oligo) 
generation programs with various screening strategies; developing and implementing bio-imaging strategies to enhance the informational output of the in vivo studies; managing the aspects of the vivarium activities 
including IACUC protocols; generating data package for the lead compounds to meet the criteria of legal 
aspects; supporting the clinical development of on-going oncology programs; monitoring outsourcing CROs in both of in vitro and in vivo studies; initiating and obtaining licenses to get access to state-of-the-art genetically 
engineered mice (GEMMs; licenses obtained from Baylor University, MIT, USCF and McMaster University). 
12 publications and 1 patent were published to cover the cancer related cachexia and non-coding RNA areas. 
One IND was filed for ISIS-STAT3Rx. The data package of ISIS-STAT3Rx ended up with a 31 million dollar 
deal with AstraZeneca.

Senior Scientist

Ionis Pharmaceuticals

Carlsbad, CA

2009 to October 2010

Established the in vivo oncology/pharmacology program emphasizing on antisense drug discovery; duties 
included: serving as the PI of oncology IACUC protocols; establishing cancer cell bank and in vivo animal system to support oncology activities; monitoring on outsourcing projects (reagent antibody generation; in vivo 
pharmacology and immunohistochemistry); developing and implementing xenograft, dissemination (Leukemia), 
orthotopic (GBM/brain and HCC/liver), and cachexia (muscle/fat wasting) models for evaluating drug 
delivery/uptake, target reduction (PD), and pharmacological efficacy on the lead ASOs (antisense oligos); 
performing Tox lean screen to evaluate the preliminary toxicity and tolerability in mouse, rat and monkey species; 
identifying and validating pharmacodynamic biomarkers for preclinical and clinical use (Meso Scale 
Discovery/MSD, and Luminex platforms); proposing and validating new therapeutic targets to strengthen 
company’s pipeline; supporting non-oncology projects with establishing and performing 2/3 partial hepatectomy. 
Achievements included: moved ISIS-STAT3Rx into clinical development. Due to the accomplished achievements, 
3 ISIS awards were granted in this period of time. 

Senior Scientist/Project Leader


Berkeley, CA

2006 to 2008

Supervised research associates focusing on both of early and late stage programs; served as the project lead 
(Novartis-Chiron/XOMA collaboration) and pharmacology representative in multiple projects (Takeda/XOMA and Schering-Plough/XOMA collaborations). Duties included: directing and performing the tests of novel 
therapeutics both in vitro and in vivo for anti-tumor effects including evaluation of such therapeutics in animal 
models of solid tumors as well as non-Hodgkin lymphoma and Hodgkin lymphoma; coordinating efforts between 
Pharmacology and Production departments in evaluation of this therapeutic for an IND filing; aiding in research 
perform with outside contractors to support the pharmacology; proposing and reviewing novel potential targets; 
supporting non-oncology projects with establishing and performing human SCID trans-xenograft- (psoriasis), 
CIA- (collagen-induced arthritis), DIO- (diet-induced obesity) and GTT- (glucose tolerance test; diabetes) mouse 
models for drug testing. 5 publications and 3 patents were published throughout this period. Generated data sets 
supported the clinical trials of Lucatumumab (formerly HCD122; anti-CD40 mAb).

Scientist II/Project Leader


Berkeley, CA

2004 to 2006

Served as the project lead in a partnered program (EphB3; in collaboration with Chiron/Novartis AG) and pharmacology representative in multiple project teams. Duties included: performing and establishing 
pharmacology due diligence at XOMA; determining the biological activity of novel antibodies in vivo, including 
model establishment, validation with standard of care and efficacy studies; leading a partnered collaborating 
project through milestone and administered the budget and FTEs for the project; monitoring on hybridoma 
generation for two specific targets; developing new animal models for the project need. A XOMA impact award 
was granted due to the achievements.

Assistant Specialist

University of California

San Francisco, CA

2002 to 2004

Led the lung cancer project to identify and characterize lung cancer modifiers using animal models and pathological analyses. Duties included: managing multiple research collaborations; supervising research 
associates; obtaining research grants; and conducting independent research into the mechanisms of tumor 
progression in lung cancer using standard cell biology/ molecular/ biochemical/ genetic/ techniques, as well as oligo-, cDNA-, CGH- microarrays, Taqman (q-PCR), IHC, and FISH; managing to maintain and breed more than 
200 cages of mouse colonies including knock-in, knock-out and transgenic mice such as K-ras-, N-ras-, H-ras-, 
TRAM-, and Blm- deficient mice by genotyping and specific breeding. 5 publications were published throughout this period.

University of California

San Francisco, CA

1999 to 2002

Characterized the biological activities of novel molecules in vitro by screening the panel of NCI 60 cancer cell 
lines and examined mRNA expression in various organs. Isolated cell lines from primary tumors and established 
cell lines by transition and stable transfections. Evaluated anti-tumor properties of potential therapeutic molecules in xenograft mouse models.

Post-Doctoral Research Fellow

ONYX Pharmaceuticals

Richmond, CA

1998 to 1999

The research goal was to exploit mouse model systems for the identification of genes that were important for cancer susceptibility or cancer progression in human populations, as a route to the discovery of novel diagnostics, 
new possibilities for prevention, or therapeutics. The main research efforts had been focus on the elucidation of the molecular mechanisms of multistage carcinogenesis, with particular emphasis on mouse models of chemically 
induced skin tumor development. Transgenic or knock-out mice were extensively used. The biological 
consequences of the genetic changes for cell behavior during transformation were also invested. Several novel 
genetic modifiers of cancer susceptibility as well as their alternative splicing forms were isolated and characterized.

Teaching and Research Assistant

The University of Arizona

Tucson, AZ

1993 to 1998

The major research goal was focused on mammalian genetics, especially as related to human development and disease. Transgenic mice were used extensively, primarily to provide animal models of human genetic diseases. 
Led a research group contributed to the positional cloning of the Niemann Pick C gene (NPC) and characterized the mechanism of action of this gene. Gene therapy of genetic renal disease (carbonic anhydrase II deficiency; CA 
II) was also performed by using retrograde injection of cationic liposome complexed with a CA II chimeric gene. 
The published report appeared to have been the first successful gene therapy of genetic renal disease. 7 
publications were published throughout this period. 

Research Associate

National Taiwan University, Department of Agronomy

Taipei, TW

1989 to 1990

Genetic analyses of soybean isogenic lines using RFLP- and PCR- markers.


Ph.D. in Genetics

The University of Arizona

Tucson, AZ

1993 to 1998

M.S. in Agronomy

University of Nebraska

Lincoln, NE

1991 to 1993

B.S. in Agronomy

National Taiwan University

Taipei, TW

1984 to 1988


PHARMACOLOGY (10+ years), TOXICOLOGY (10+ years), VIVO (10+ years), MOUSE (10+ years), ADME (10+ years)

Additional Information

• DNA: subcloning, plasmid construction; PCR; pulse field gel; Southern blot; slot-blot; sequencing; RFLP and 
• RNA and cDNA: TaqMan (qPCR) assay; Northern blot; RNAse protect assay; RT-PCR; in vitro 
transcription; and 5′, 3′- RACE. 
• Protein and Immunology: standard assay; SDS PAGE; Western blot; silver stain; column purification; 
• Physical mapping: YAC and BAC library screening; identification of novel micro-satellite markers; cosmid 
library construction and Fluorescence In Situ Hybridization (FISH). 
• Microarray: CGH-, cDNA-, and oligo- microarrays. 
• Antibody: Antibody-dependent cellular cytotoxicity (ADCC) assays (LDH & Calcein-AM methods). 
• Biomarker & translational research: Meso Scale Doscovery (MSD); QuantiGene (Luminex); QuantiGene 
Plex assay (Affymetrix); and Millipore xMAP technology alyzier. 
• Virus works: Adeno virus titer; purification; and cell infection. 
• Histology: laser capture microdissection (LCM); tissue staining; frozen section preparation; in situ 
hybridization (Quantigene ViewRNA, Affymetrix); and Aperio (Digital pathology information system). 
• Animal work: perfusion and imaging, injections (i.v., i.p., and s.c.); oral gavage and cardiac puncher; 
catheter implantation; organs and bone marrow harvesting; implantation of alzet osmotic pumps; 
microsurgeries; and Stereotaxy. 
• In vitro cell base assay: transient and stable transfections; wound healing and migration assays; cell staining; 
introducing intact Yeast Artificial Chromosomes (YACs) into mammalian cells; FACS analysis; mouse lung 
cell isolation and collagen gel assay; establishment of new cell lines from primary tumors and human PBMC 
preparation; and cell counting by Z1 and Vi-Cell Courter counters (Beckman). 
• In vivo pharmacology (oncology): syngeneic- (immuno-oncology), CD34+ humanized- (immuno-oncology), 
xenograft- (including patient derived xenografts, PDXs), orthotopic- (bladder, cecum, liver, mammary fat 
pad, pancreas and brain), allograft- (skin), survival-, transgenic-, knock in/out-, and angiogenesis- mouse 
models; in vivo serial tumor passage; and BMDS/ Studylog data system. 
• In vivo pharmacology (non-oncology): 2/3 partial hepatectomy; human SCID trans-xenograft, CIA, GTT, 
DIO, ITP, lupus, cGvHD, and denervation atrophy. 
• Toxicology: Blood and urine chemistry (Olympus AU400e); and biomarkers for pancreatic injury. 
• In vivo molecular imaging: Wizard Gamma counter; EnViso; CareStream (Korda); Optix; CT/PET 
(INVEON, Siemens; using both of contract reagents and 124I isotope); and IVIS Spectrum (Caliper/PE).

Find More Resume Samples for Director (Immuno-Pharmacology) Job Title. For related job vacancies click here.

Top-100 Resume Sample Templates By Job Title/Field/Industry

A Résumé or CV is a marketing tool that seeks to highlight the applicant's skills, experiences, and the most relevant accomplishments to the job or position, it should deliver its message to its intended audience (the employer) accurately... BROWSE RESUMES.

If you would like to explore how professional career counseling can benefit you .. kindly, send your inquiry via Email: